NEWS RELEASE

Teijin Applies for Approval to Manufacture and Sell
Abaloparatide Acetate as Osteoporosis Treatment in JapanTokyo, Japan, May 27, 2020 --- Teijin Pharma Limited, the core company of the TeijinGroup’s healthcare business, announced today that it has applied for approval in Japanto manufacture and sell abaloparatide acetate, a therapeutic drug known generically asITM-058, as an indication for osteoporosis to promote bone formation in patients withhigh risk of bone fractures.
Abaloparatide acetate, a derivative of the human parathyroid hormone-related peptide(hPTHrP), selectively stimulates the G protein-coupled parathyroid hormone type 1
receptor. In a phase III clinical trial conducted in Japan for osteoporosis patients with ahigh risk of bone fractures, a significant effect on lumbar spine bone mineral density wasobserved as the trial’s efficacy endpoint. The Japan trial produced no major differencecompared to other global studies in terms of drug safety and no new side effect wasobserved in Japanese patients.
“Under the Teijin Group’s current medium-term management plan, we are contributing tosustainability by developing solutions for a demographic change and increased healthconsciousness,” said Ichiro Watanabe, president of Teijin Pharma Limited. “LaunchingITM-058 will be a key factor in our implementation of this plan, so we hope to obtainapproval and begin marketing ITM-058 to improve patients’ quality of life (QOL) as soon
as possible.”“We are pleased that our partner Teijin has achieved this significant milestone toward
the potential introduction of abaloparatide as a new treatment option for osteoporosis
patients,” stated Kelly Martin, CEO of Radius. “Japan represents the largest anabolic
market in the world. This is a critically important step in expanding our osteoporosis
business globally.”In April 2017, Radius Health, Inc. received manufacturing and sales approval in theUnited States for ITM-058 as a medication for treating postmenopausal osteoporosis inpatients with a high risk of bone fractures.
Japan is estimated to have about 13 million patients with osteoporosis (*1), many ofwhom are at risk of suffering bone fractures that could greatly reduce their activities ofdaily living (ADL) and QOL. Osteoporosis is particularly troublesome for people who have
low bone density, bone fragility or a high frequency of fractures due to aging. There is astrong demand in Japan for therapeutic drugs capable of increasing bone mass quickly
to help patients avoid debilitating bone fractures.
(*1) Guidelines for Prevention AND Treatment of OSTEOPOROSIS 2015

Teijin Pharma contributes to improved QOL of patients through solutions related to bones
and joints, including its osteoporosis drugs Onealfa® and Bonalon® (*2) and sonicaccelerated fracture healing system SAFHS®.
(*2) Bonalon® is the registered trademark of Merck Sharp & Dohme Corp., Whitehouse Station,NJ, USA.

About Radius
Radius is a science-driven fully integrated biopharmaceutical company that is committed
to developing and commercializing innovative endocrine therapeutics. Radius’ leadproduct, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug
Administration for the treatment of postmenopausal women with osteoporosis at high risk
for fracture. The Radius clinical pipeline includes the investigational use of abaloparatide
injection for the treatment of men with osteoporosis, an investigational abaloparatidepatch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901)
for potential use in hormone-receptor positive breast cancer; and the investigational drug
RAD140, a non-steroidal, selective androgen receptor modulator (SARM) underinvestigation for potential use in hormone-receptor positive breast cancer. For more
information, please visit www.radiuspharm.com.
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services fordigital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions”, Teijin aims to be a company that
supports the society of the future. The group comprises more than 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 853.7 billion (USD 8.0 billion) and total assets of JPY 1,004.2 billion (USD9.4 billion) in the fiscal year that ended on March 31, 2020.
Press ContactCorporate Communications
Teijin Limited
pr@teijin.co.jp